Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 18

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

(unaudited)

Common StockSharesCommon Stock and Paid-InCapitalAccumulatedOtherComprehensiveIncome (loss)AccumulatedDeficitStock Held inTrustTotalStockholders’EquityBalance at July 1, 202594,126 $2,334,538 $1,621 $(1,164,521)$(112)$1,171,526 Exercise of stock options417 7,452 — — — 7,452 Issuance of common stock upon vesting of restricted stock units5 — — — — — Stock-based compensation— 22,702 — — — 22,702 Other— 7 — — — 7 Other comprehensive income— — 573 — — 573 Net loss— — — (130,091)— (130,091)Balance at September 30, 202594,548 $2,364,699 $2,194 $(1,294,612)$(112)$1,072,169 Balance at January 1, 202592,926 $2,275,952 $963 $(952,110)$— $1,324,805 Exercise of stock options1,095 16,433 — — — 16,433 Stock issued under Employee Stock Purchase Plan115 2,880 — — — 2,880 Issuance of common stock upon vesting of restricted stock units412 — — — — — Stock-based compensation— 69,304 — — — 69,304 Stock held in trust under deferred compensation plan— 112 — — (112)— Other— 18 — — — 18 Other comprehensive income— — 1,231 — — 1,231 Net loss— — — (342,502)— (342,502)Balance at September 30, 202594,548 $2,364,699 $2,194 $(1,294,612)$(112)$1,072,169 Balance at July 1, 202479,322 $1,625,640 $(190)$(794,687)$— $830,